From Hypertension to Stroke: Mechanisms and Potential Prevention Strategies

CNS Neuroscience and Therapeutics

Volumn 17, Issue 5, 2011, Pages 577-584

  Yu, Jian Guang ^a   Zhou, Rui Rui ^a,b   Cai, Guo Jun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Shanghai Xuhui District Central Hospital   (China)

Author keywords

Arterial baroreflex; Hypertension; Inflammation; Oxidative stress; Stroke prevention

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROGEN; KETANSERIN; OLMESARTAN; PIOGLITAZONE; RAMIPRIL; ROSUVASTATIN; TELMISARTAN; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; BRAIN BLOOD FLOW; COMORBIDITY; DRUG MECHANISM; ELECTROSTIMULATION THERAPY; HUMAN; HYPERTENSION; INFLAMMATION; KINESIOTHERAPY; LIFESTYLE MODIFICATION; NONHUMAN; OXIDATIVE STRESS; PRESSORECEPTOR REFLEX; REVIEW; RISK FACTOR; STROKE; VAGUS NERVE STIMULATION; WEIGHT REDUCTION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RISK FACTORS; STROKE;

EID: 80053198167     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2011.00264.x     Document Type: Review

References (157)

1. Flynn RW, MacWalter RS, Doney AS. The cost of cerebral ischaemia. Neuropharmacology 2008;55:250-256.
2. World health statistics 2008. Geneva, Switzerland: World Health Organization, 2008.
3. Jia Q, Liu LP, Wang YJ. Stroke in China. Clin Exp Pharmacol Physiol 2010;37:259-264.
4. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics-2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-e146.
5. Palmer AJ, Valentine WJ, Roze S, Lammert M, Spiesser J, Gabriel S. Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries. Curr Med Res Opin 2005;21:19-26.
6. Mackay J, Mensah G. The atlas of heart disease and stroke. Geneva, Switzerland: World Health Organization, 2004.
7. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Circulation 2006;113:e409-e449.
8. Bazzano LA, Gu D, Whelton MR, et al. Body mass index and risk of stroke among Chinese men and women. Ann Neurol 2010;67:11-20.
9. Bangalore S, Messerli FH, Wun CC, et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J 2010;31:2897-2908.
10. Bangalore S, Messerli FH, Franklin SS, Mancia G, Champion A, Pepine CJ. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: An INternational VErapamil SR-trandolapril STudy (INVEST) analysis. Eur Heart J 2009;30:1395-1401.
11. Arumugam TV, Phillips TM, Cheng A, Morrell CH, Mattson MP, Wan R. Age and energy intake interact to modify cell stress pathways and stroke outcome. Ann Neurol 2010;67:41-52.
12. Morgenstern LB, Escobar JD, Sanchez BN, et al. Fast food and neighborhood stroke risk. Ann Neurol 2009;66:165-170.
13. Goldstein LB. Eating yourself to a stroke? Ann Neurol 2009;66:129-131.
14. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.
15. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513-1518.
16. Gorelick PB. New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurol 2002;1:149-156.
17. Dahlof B. Prevention of stroke in patients with hypertension. Am J Cardiol 2007;100:17J-24J.
18. Lammie GA. Hypertensive cerebral small vessel disease and stroke. Brain Pathol 2002;12:358-370.
19. Gkaliagkousi E, Corrigall V, Becker S, et al. Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension. Eur Heart J 2009;30:3048-3054.
20. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial stiffness. Hypertension 2005;45:1050-1055.
21. Baumbach GL, Heistad DD. Cerebral circulation in chronic arterial hypertension. Hypertension 1988;12:89-95.
22. Benjo A, Thompson RE, Fine D, et al. Pulse pressure is an age-independent predictor of stroke development after cardiac surgery. Hypertension 2007;50:630-635.
23. Baumbach GL, Heistad DD, Siems JE. Effect of sympathetic nerves on composition and distensibility of cerebral arterioles in rats. J Physiol 1989;416:123-140.
24. O'Callaghan CJ, Williams B. Mechanical strain-induced extracellular matrix production by human vascular smooth muscle cells: Role of TGF-beta(1). Hypertension 2000;36:319-324.
25. Harrison DG, Widder J, Grumbach I, Chen W, Weber M, Searles C. Endothelial mechanotransduction, nitric oxide and vascular inflammation. J Intern Med 2006;259:351-363.
26. Schiffrin EL, Touyz RM. From bedside to bench to bedside: Role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol 2004;287:H435-H446.
27. Flamant M, Placier S, Dubroca C, et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension 2007;50:212-218.
28. Heerkens EH, Izzard AS, Heagerty AM. Integrins, vascular remodeling, and hypertension. Hypertension 2007;49:1-4.
29. Zacchigna L, Vecchione C, Notte A, et al. Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell 2006;124:929-942.
30. Faury G, Pezet M, Knutsen RH, et al. Developmental adaptation of the mouse cardiovascular system to elastin haploinsufficiency. J Clin Invest 2003;112:1419-1428.
31. Chillon JM, Baumbach GL. Effects of an angiotensin-converting enzyme inhibitor and a beta-blocker on cerebral arterioles in rats. Hypertension 1999;33:856-861.
32. Izzard AS, Horton S, Heerkens EH, Shaw L, Heagerty AM. Middle cerebral artery structure and distensibility during developing and established phases of hypertension in the spontaneously hypertensive rat. J Hypertens 2006;24:875-880.
33. Beason-Held LL, Moghekar A, Zonderman AB, Kraut MA, Resnick SM. Longitudinal changes in cerebral blood flow in the older hypertensive brain. Stroke 2007;38:1766-1773.
34. O'Sullivan M, Lythgoe DJ, Pereira AC, et al. Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis. Neurology 2002;59:321-326.
35. Jennings JR, Muldoon MF, Ryan C, et al. Reduced cerebral blood flow response and compensation among patients with untreated hypertension. Neurology 2005;64:1358-1365.
36. Yang ST, Mayhan WG, Faraci FM, Heistad DD. Endothelium-dependent responses of cerebral blood vessels during chronic hypertension. Hypertension 1991;17:612-618.
37. Barry DI. Cerebral blood flow in hypertension. J Cardiovasc Pharmacol 1985;7(Suppl 2):S94-S98.
38. Paulson OB, Strandgaard S, Edvinsson L. Cerebral autoregulation. Cerebrovasc Brain Metab Rev 1990;2:161-192.
39. Chrissobolis S, Sobey CG. Recent evidence for an involvement of rho-kinase in cerebral vascular disease. Stroke 2006;37:2174-2180.
40. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 2003;63:179-185.
41. Sindhu RK, Koo JR, Roberts CK, Vaziri ND. Dysregulation of hepatic superoxide dismutase, catalase and glutathione peroxidase in diabetes: Response to insulin and antioxidant therapies. Clin Exp Hypertens 2004;26:43-53.
42. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004;13:93-99.
43. Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: Oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2006;2:582-593.
44. Vaziri ND, Wang XQ, Oveisi F, Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 2000;36:142-146.
45. Sindhu RK, Roberts CK, Ehdaie A, Zhan CD, Vaziri ND. Effects of aortic coarctation on aortic antioxidant enzymes and NADPH oxidase protein expression. Life Sci 2005;76:945-953.
46. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
47. Ong SL, Zhang Y, Whitworth JA. Reactive oxygen species and glucocorticoid-induced hypertension. Clin Exp Pharmacol Physiol 2008;35:477-482.
48. Chandramohan G, Bai Y, Norris K, Rodriguez-Iturbe B, Vaziri ND. Effects of dietary salt on intrarenal angiotensin system, NAD(P)H oxidase, COX-2, MCP-1 and PAI-1 expressions and NF-kappaB activity in salt-sensitive and -resistant rat kidneys. Am J Nephrol 2008;28:158-167.
49. Hirooka Y. Role of reactive oxygen species in brainstem in neural mechanisms of hypertension. Auton Neurosci 2008;142:20-24.
50. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87:315-424.
51. Faraci FM. Reactive oxygen species: Influence on cerebral vascular tone. J Appl Physiol 2006;100:739-743.
52. Kazama K, Anrather J, Zhou P, et al. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res 2004;95:1019-1026.
53. Girouard H, Park L, Anrather J, Zhou P, Iadecola C. Cerebrovascular nitrosative stress mediates neurovascular and endothelial dysfunction induced by angiotensin II. Arterioscler Thromb Vasc Biol 2007;27:303-309.
54. Henry PD, Chen CH. Inflammatory mechanisms of atheroma formation. Influence of fluid mechanics and lipid-derived inflammatory mediators. Am J Hypertens 1993;6:328S-334S.
55. Chyatte D, Bruno G, Desai S, Todor DR. Inflammation and intracranial aneurysms. Neurosurgery 1999;45:1137-1146; discussion 1146-1137.
56. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: The Edinburgh Artery Study. Circulation 2007;115:2119-2127.
57. McColl BW, Allan SM, Rothwell NJ. Systemic infection, inflammation and acute ischemic stroke. Neuroscience 2009;158:1049-1061.
58. Wang Q, Ding H, Tang JR, et al. C-reactive protein polymorphisms and genetic susceptibility to ischemic stroke and hemorrhagic stroke in the Chinese Han population. Acta Pharmacol Sin 2009;30:291-298.
59. Ridker PM. Psoriasis, inflammation, and vascular risk: A problem more than skin deep? Eur Heart J 2010;31:902-904.
60. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000-1006.
61. Liao W, Wei Y, Yu C, et al. Prenatal exposure to zymosan results in hypertension in adult offspring rats. Clin Exp Pharmacol Physiol 2008;35:1413-1418.
62. Yoon JW, Pahl MV, Vaziri ND. Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int 2007;71:167-172.
63. Kim CH, Vaziri ND. Hypertension promotes integrin expression and reactive oxygen species generation by circulating leukocytes. Kidney Int 2005;67:1462-1470.
64. Bravo Y, Quiroz Y, Ferrebuz A, Vaziri ND, Rodriguez-Iturbe B. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol 2007;293:F616-F623.
65. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND. Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 2005;315:51-57.
66. Nava M, Quiroz Y, Vaziri N, Rodriguez-Iturbe B. Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol 2003;284:F447-F454.
67. Persson PB. Baroreflexes in hypertension: A mystery revisited. Hypertension 2005;46:1095-1096.
68. La Rovere MT, Pinna GD, Hohnloser SH, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: Implications for clinical trials. Circulation 2001;103:2072-2077.
69. Ormezzano O, Cracowski JL, Quesada JL, Pierre H, Mallion JM, Baguet JP. Evaluation of the prognostic value of BARoreflex sensitivity in hypertensive patients: The EVABAR study. J Hypertens 2008;26:1373-1378.
70. Cai GJ, Miao CY, Xie HH, Lu LH, Su DF. Arterial baroreflex dysfunction promotes atherosclerosis in rats. Atherosclerosis 2005;183:41-47.
71. Shu H, Yi-Ming W, Xu LP, Miao CY, Su DF. Increased susceptibility of ventricular arrhythmias to aconitine in anaesthetized rats is attributed to the inhibition of baroreflex. Clin Exp Pharmacol Physiol 2004;31:249-253.
72. Shen FM, Guan YF, Xie HH, Su DF. Arterial baroreflex function determines the survival time in lipopolysaccharide-induced shock in rats. Shock 2004;21:556-560.
73. Bristow JD, Honour AJ, Pickering GW, Sleight P, Smyth HS. Diminished baroreflex sensitivity in high blood pressure. Circulation 1969;39:48-54.
74. Eveson DJ, Robinson TG, Shah NS, Panerai RB, Paul SK, Potter JF. Abnormalities in cardiac baroreceptor sensitivity in acute ischaemic stroke patients are related to aortic stiffness. Clin Sci (Lond) 2005;108:441-447.
75. Sykora M, Diedler J, Rupp A, Turcani P, Rocco A, Steiner T. Impaired baroreflex sensitivity predicts outcome of acute intracerebral hemorrhage. Crit Care Med 2008;36:3074-3079.
76. Liu AJ, Ma XJ, Shen FM, Liu JG, Chen H, Su DF. Arterial baroreflex: A novel target for preventing stroke in rat hypertension. Stroke 2007;38:1916-1923.
77. Immink RV, van Montfrans GA, Stam J, Karemaker JM, Diamant M, van Lieshout JJ. Dynamic cerebral autoregulation in acute lacunar and middle cerebral artery territory ischemic stroke. Stroke 2005;36:2595-2600.
78. Sykora M, Diedler J, Turcani P, Rupp A, Steiner T. Subacute perihematomal edema in intracerebral hemorrhage is associated with impaired blood pressure regulation. J Neurol Sci 2009;284:108-112.
79. Liu AJ, Ling G, Wu J, et al. Arterial baroreflex function is an important determinant of acute cerebral ischemia in rats with middle cerebral artery occlusion. Life Sci 2008;83:388-393.
80. Robinson TG, Dawson SL, Eames PJ, Panerai RB, Potter JF. Cardiac baroreceptor sensitivity predicts long-term outcome after acute ischemic stroke. Stroke 2003;34:705-712.
81. Stead LG, Gilmore RM, Vedula KC, Weaver AL, Decker WW, Brown RD, Jr. Impact of acute blood pressure variability on ischemic stroke outcome. Neurology 2006;66:1878-1881.
82. Dawson SL, Manktelow BN, Robinson TG, Panerai RB, Potter JF. Which parameters of beat-to-beat blood pressure and variability best predict early outcome after acute ischemic stroke? Stroke 2000;31:463-468.
83. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005;365:217-223.
84. Grassi G, Arenare F, Trevano FQ, Dell'Oro R, Mancia AG. Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials. Curr Hypertens Rep 2007;9:299-304.
85. McAlister FA, Feldman RD, Wyard K, Brant R, Campbell NR. The impact of the Canadian hypertension education programme in its first decade. Eur Heart J 2009;30:1434-1439.
86. Buijsse B, Weikert C, Drogan D, Bergmann M, Boeing H. Chocolate consumption in relation to blood pressure and risk of cardiovascular disease in German adults. Eur Heart J 2010;31:1616-1623.
87. Johnston SC, Sidney S, Hills NK, et al. Standardized discharge orders after stroke: Results of the quality improvement in stroke prevention (QUISP) cluster randomized trial. Ann Neurol 2010;67:579-589.
88. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: A meta-analysis. Lancet 2001;358:1305-1315.
89. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008;24:121-127.
90. Brugts JJ, Ninomiya T, Boersma E, et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: A combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J 2009;30:1385-1394.
91. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
92. Pitt B. Angiotensin-converting enzyme inhibitors in patients with vascular disease. Eur Heart J 2009;30:1307-1309.
93. Messerli FH, Bangalore S, Ruschitzka F. Angiotensin receptor blockers: Baseline therapy in hypertension? Eur Heart J 2009;30:2427-2430.
94. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535.
95. Sawada T, Yamada H, Dahlof B, Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009;30:2461-2469.
96. Strauss MH, Hall AS. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2010;31:261-262; author reply 262.
97. Wang JG. A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention. Vasc Health Risk Manag 2009;5:593-605.
98. Papadopoulos DP, Papademetriou V. Aggressive blood pressure control and stroke prevention: Role of calcium channel blockers. J Hypertens 2008;26:844-852.
99. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: An overview of published reviews. Stroke 2004;35:1024.
100. Bangalore S, Messerli FH. A review of stroke in patients with hypertension and coronary artery disease: Focus on calcium channel blockers. Int J Clin Pract 2006;60:1281-1286.
101. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-886.
102. Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007;369:1431-1439.
103. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363:2022-2031.
104. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: A quantitative overview. Hypertension 2007;50:181-188.
105. Mortsell D, Malmqvist K, Held C, Kahan T. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: The Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. J Intern Med 2007;261:472-479.
106. Lu JC, Cui W, Zhang HL, et al. Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2009;36:1110-1119.
107. Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 2000;31:2478-2486.
108. Ono H, Minatoguchi S, Watanabe K, et al. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Hypertens Res 2008;31:271-279.
109. Ando H, Zhou J, Macova M, Imboden H, Saavedra JM. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 2004;35:1726-1731.
110. Munzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J 2010;31:2741-2748.
111. Vaziri ND. Causal link between oxidative stress, inflammation, and hypertension. Iran J Kidney Dis 2008;2:1-10.
112. Roberts CK, Vaziri ND, Barnard RJ. Effect of diet and exercise intervention on blood pressure, insulin, oxidative stress, and nitric oxide availability. Circulation 2002;106:2530-2532.
113. Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med 2007;13:688-694.
114. Cai J, Kang Z, Liu WW, et al. Hydrogen therapy reduces apoptosis in neonatal hypoxia-ischemia rat model. Neurosci Lett 2008;441:167-172.
115. Cai J, Kang Z, Liu K, et al. Neuroprotective effects of hydrogen saline in neonatal hypoxia-ischemia rat model. Brain Res 2009;1256:129-137.
116. Gharib B, Hanna S, Abdallahi OM, Lepidi H, Gardette B, De Reggi M. Anti-inflammatory properties of molecular hydrogen: Investigation on parasite-induced liver inflammation. C R Acad Sci III 2001;324:719-724.
117. Androulakis ES, Tousoulis D, Papageorgiou N, Tsioufis C, Kallikazaros I, Stefanadis C. Essential hypertension: Is there a role for inflammatory mechanisms? Cardiol Rev 2009;17:216-221.
118. Tousoulis D, Kourtellaris P, Antoniades C, et al. Effects of tirbesartan and perindopril on forearm reactive hyperemia and inflammatory process, in normotensive patients with coronary artery disease. Int J Cardiol 2008;124:127-129.
119. Brili S, Tousoulis D, Antoniades C, et al. Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: A randomized cross-over study. J Am Coll Cardiol 2008;51:742-749.
120. Chujo D, Yagi K, Asano A, et al. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res 2007;30:1205-1210.
121. Chitravas N, Dewey HM, Nicol MB, Harding DL, Pearce DC, Thrift AG. Is prestroke use of angiotensin-converting enzyme inhibitors associated with better outcome? Neurology 2007;68:1687-1693.
122. Rosei EA, Rizzoni D, Muiesan ML, et al. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J Hypertens 2005;23:435-444.
123. Jilma B, Li-Saw-Hee FL, Wagner OF, Beevers DG, Lip GY. Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. Clin Sci (Lond) 2002;103:131-136.
124. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-331.
125. Zimmermann R, Kastens J, Linz W, Wiemer G, Scholkens BA, Schaper J. Effect of long-term ACE inhibition on myocardial tissue in hypertensive stroke-prone rats. J Mol Cell Cardiol 1999;31:1447-1456.
126. Fleming I. Signaling by the angiotensin-converting enzyme. Circ Res 2006;98:887-896.
127. Kovanen PT. Mast cells: Multipotent local effector cells in atherothrombosis. Immunol Rev 2007;217:105-122.
128. Li M, Liu K, Michalicek J, et al. Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J Clin Invest 2004;114:112-120.
129. Fujimi K, Uehara Y, Abe S, et al. Homocysteine-induced oxidative stress upregulates chymase in mouse mastocytoma cells. Hypertens Res 2010;33:149-154.
130. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: From folate fortification to the recent clinical trials. Eur Heart J 2009;30:6-15.
131. Sanchez-Patan F, Aller MA, Cuellar C, et al. Mast cell inhibition by ketotifen reduces splanchnic inflammatory response in a portal hypertension model in rats. Exp Toxicol Pathol 2008;60:347-355.
132. Yusof M, Kamada K, Gaskin FS, Korthuis RJ. Angiotensin II mediates postischemic leukocyte-endothelial interactions: Role of calcitonin gene-related peptide. Am J Physiol Heart Circ Physiol 2007;292:H3032-H3037.
133. Milionis HJ, Liberopoulos EN, Elisaf MS, Mikhailidis DP. Analysis of antihypertensive effects of statins. Curr Hypertens Rep 2007;9:175-183.
134. Marti-Fabregas J, Gomis M, Arboix A, et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004;35:1117-1121.
135. Naval NS, Abdelhak TA, Urrunaga N, Zeballos P, Mirski MA, Carhuapoma JR. An association of prior statin use with decreased perihematomal edema. Neurocrit Care 2008;8:13-18.
136. Klingenberg R, Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease: Emerging therapies. Eur Heart J 2009;30:2838-2844.
137. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: A controlled randomized study. Neurology 2007;69:904-910.
138. Takase H, Nakazawa A, Yamashita S, et al. Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers. Metabolism 2007;56:559-564.
139. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421:384-388.
140. Hiramoto T, Chida Y, Sonoda J, Yoshihara K, Sudo N, Kubo C. The hepatic vagus nerve attenuates Fas-induced apoptosis in the mouse liver via alpha7 nicotinic acetylcholine receptor. Gastroenterology 2008;134:2122-2131.
141. Rosas-Ballina M, Goldstein RS, Gallowitsch-Puerta M, et al. The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol Med 2009;15:195-202.
142. Giebelen IA, van Westerloo DJ, LaRosa GJ, de Vos AF, van der Poll T. Local stimulation of alpha7 cholinergic receptors inhibits LPS-induced TNF-alpha release in the mouse lung. Shock 2007;28:700-703.
143. Mortara A, La Rovere MT, Pinna GD, Maestri R, Capomolla S, Cobelli F. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 2000;36:1612-1618.
144. Laowattana S, Oppenheimer SM. Protective effects of beta-blockers in cerebrovascular disease. Neurology 2007;68:509-514.
145. Savitz SI, Erhardt JA, Anthony JV, et al. The novel beta-blocker, carvedilol, provides neuroprotection in transient focal stroke. J Cereb Blood Flow Metab 2000;20:1197-1204.
146. Liu MY. Protective effects of propranolol on experimentally head-injured mouse brains. J Formos Med Assoc 1995;94:386-390.
147. Cotton BA, Snodgrass KB, Fleming SB, et al. Beta-blocker exposure is associated with improved survival after severe traumatic brain injury. J Trauma 2007;62:26-33; discussion 33-25.
148. Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JR. Low dose beta blockade in acute stroke ("BEST" trial): An evaluation. Br Med J (Clin Res Ed) 1988;296:737-741.
149. Potter JF, Robinson TG, Ford GA, et al. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): A randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol 2009;8:48-56.
150. Fu YJ, Shu H, Miao CY, Wang MW, Su DF. Restoration of baroreflex function by ketanserin is not blood pressure dependent in conscious freely moving rats. J Hypertens 2004;22:1165-1172.
151. Liu AJ, Guo JM, Xia W, Su DF. New strategies for the prevention of stroke. Clin Exp Pharmacol Physiol 2010;37:265-271.
152. Sykora M, Diedler J, Turcani P, Hacke W, Steiner T. Baroreflex: A new therapeutic target in human stroke? Stroke 2009;40:e678-e682.
153. Ma XJ, Shen FM, Liu AJ, Shi KY, Wu YL, Su DF. Clonidine, moxonidine, folic acid, and mecobalamin improve baroreflex function in stroke-prone, spontaneously hypertensive rats. Acta Pharmacol Sin 2007;28:1550-1558.
154. Toader E, Cividjian A, Quintin L. Recruitment of cardiac parasympathetic activity: Effects of clonidine on cardiac vagal motoneurones, pressure lability, and cardiac baroreflex slope in rats. Br J Anaesth 2009;102:322-330.
155. Wang JL, Wang L, Wu ZT, et al. Low dose of moxonidine within the rostral ventrolateral medulla improves the baroreflex sensitivity control of sympathetic activity in hypertensive rat. Acta Pharmacol Sin 2009;30:1594-1600.
156. Wustmann K, Kucera JP, Scheffers I, et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009;54:530-536.
157. Ay I, Lu J, Ay H, Gregory Sorensen A. Vagus nerve stimulation reduces infarct size in rat focal cerebral ischemia. Neurosci Lett 2009;459:147-151.